Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

Drug master file explained: DMF types, letter of authorization and the FY 2027 Type II DMF fee of 109,899 dollars, with 47 API Form 483s and 18 API warning letters in 2025.
FDA Databases & Guidance

Drug master file (DMF): types, letter of authorization, GDUFA fee and what FDA finds at API facilities

What a drug master file is under 21 CFR 314.420, the four DMF types still open (II, III, IV and V; Type I was removed in 2000), how a letter of authorization lets an ANDA, NDA or IND reference the file, the GDUFA Type II API DMF fee and initial completeness assessment, and why FDA inspects the DMF holder's facility. Ends with Atlas data on API manufacturers: 47 Form 483s at registered API facilities from January 2025 to July 2026, API warning letters by year since 2021, and the inspection record of six API facilities that received letters in 2025 and 2026.

Read more
GAMP 5 categories cover: 21 CFR 211.68 was cited at 172 of 774 drug inspections, 22.2%, January 2025 to October 2026.
Data Integrity & CSV

GAMP 5: software categories, the second edition, and the 211.68 citations they map to

GAMP 5 is ISPE's risk-based guide to validating GxP computerized systems. This guide explains software categories 1, 3, 4 and 5, what the July 2022 second edition changed, whether GAMP 5 is required, what 21 CFR 211.68 asks of computerized systems, and how each category maps to the 183 citations FDA investigators wrote under 211.68 at 774 Part 211 drug inspections closed January 2025 to October 2026.

Read more
GMP audit checklist: 40 yes/no checks weighted by FDA data, with 74.4% of 753 drug inspections citing the quality system and 56.5% ending OAI when four to six systems are cited.
Inspection Readiness

GMP audit checklist: 40 yes/no checks across FDA's six systems, weighted by 753 inspections

A GMP audit checklist of 40 yes/no questions organized by the six systems in FDA Compliance Program 7356.002 (quality, facilities and equipment, materials, production, packaging and labeling, laboratory controls). Each system is weighted by how often FDA cited it in 753 drug inspections with a 21 CFR Part 211 citation that ended January 2025 to June 2026, and by its OAI rate when cited. Includes how to run the checklist before an FDA inspection and how to adapt it for a supplier or vendor audit.

Read more
Purified water system cover: FDA cited equipment cleaning under 211.67 at 237 of 774 drug inspections from January 2025 to September 2026.
CAPA & Quality Systems

Purified water system: design, monitoring and what FDA cites

What a purified water system is and how it is built, from feed water and pretreatment through reverse osmosis, storage and the distribution loop; the TOC and conductivity tests and the 100 CFU/mL microbial action level; how FDA's high purity water inspection guide frames validation and sampling; and how FDA wrote up water system failures on drug Form 483s and warning letters, with Atlas data on 774 Part 211 drug inspections that closed from January 2025 to September 2026.

Read more
CDMO FDA inspections cover: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI.
Supplier Quality

CDMO: what it is, how FDA inspects contract facilities, and how to vet one

A CDMO develops and manufactures drugs for other companies under contract. This guide covers the definition, how FDA treats a contract facility as an extension of the sponsor under 21 CFR 200.10(b) and 211.22(a), and an Atlas analysis of FDA's inspection data: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI against 16.0% at other drug facilities, the 21 CFR Part 211 sections FDA cites most at CDMOs, five OAIs that became warning letters, and a five-step check of a CDMO's inspection record.

Read more
CMO vs CDMO vs CRO cover: FDA cited ISO 13485 supplier controls at 84 of 377 device inspections, 22.3%, in the first eight months of the QMSR.
Supplier Quality

Contract manufacturing organization: CMO vs CDMO vs CRO, and who FDA holds responsible

A contract manufacturing organization (CMO) makes, packages or tests drug and device products for the company that owns them. This guide explains how a CMO differs from a CDMO and a CRO, why the owner's quality unit keeps release responsibility under 21 CFR 211.22(a) and 200.10(b) while a CRO can take over sponsor duties in writing under 21 CFR 312.52, what a quality agreement with a CMO has to assign, how often FDA cited owners for weak outsourcing controls on 774 drug and 377 device inspections from January 2025 to October 2026, and what recent Form 483s at contract facilities show.

Read more
USP 71 sterility testing cover: 121 of 158 inspections citing 21 CFR 211.167(a), 76.6%, ended OAI against 16.8% of the rest.
CAPA & Quality Systems

USP 71 sterility test: methods, sample sizes, and what FDA cites

What the USP 71 sterility test is, how membrane filtration and direct inoculation differ, which media, temperatures and growth promotion organisms the chapter sets, how many containers to test per batch, when a positive result can be invalidated, how 21 CFR 211.167(a) and 610.12 apply, and what FDA cited at 158 drug inspections that recorded a 211.167(a) sterility or pyrogen testing citation between October 2008 and September 2026.

Read more
Water for injection cover: FDA cited 21 CFR 211.67 at 237 of 774 drug inspections, and 40.5% of those ended OAI.
CAPA & Quality Systems

Water for injection: WFI vs purified water specs and what FDA cites

What water for injection (WFI) is, how it differs from purified water on endotoxin, microbial action levels and production method, how a WFI generation, storage and distribution system is designed and monitored, and how FDA cited 21 CFR 211.48 (plumbing and potable water) and 211.67 (equipment cleaning and maintenance) at 774 Part 211 drug inspections from January 2025 to September 2026, with named Form 483 examples.

Read more
21 CFR Part 58: what FDA cites in GLP inspections, with 30 Form 483s and 109 observations, 19 forms citing the study director rule 58.33 and 6 GLP warning letters, 2025 to 2026.
GMP & GxP Compliance

21 CFR Part 58: good laboratory practice for nonclinical studies, and what FDA cites

What 21 CFR Part 58, FDA's good laboratory practice rule for nonclinical laboratory studies, requires: subparts A to K, the study director (58.33), the quality assurance unit (58.35), protocol and final report content, and record retention (58.195). Includes a GLP vs GMP comparison, the status of FDA's 2016 proposed GLP rule, and Atlas data on 30 Form 483s that cited Part 58 from January 2025 to June 2026 plus six GLP warning letters.

Read more
NDSRI limits: 26.5 to 1,500 ng per day by potency category, with FDA's interim limits extended to August 2027 and 0 of 510 drug CGMP warning letters naming a nitrosamine.
CAPA & Quality Systems

NDSRI: FDA acceptable intake limits, the CPCA categories, and what came after August 2025

What a nitrosamine drug substance-related impurity (NDSRI) is and how it differs from small-molecule nitrosamines such as NDMA and NDEA, the five potency categories and acceptable intake limits in FDA's August 2023 guidance, how ICH M7(R2) frames them, what FDA posted after the August 1, 2025 deadline, and what Atlas found when it searched the full text of 510 drug CGMP warning letters dated January 2021 to October 2026.

Read more
USP 788 cover: 10 and 25 micron particulate limits for injections, with 98 sterile drug inspections citing 211.113(b) and 54.1% of them ending OAI against 23.5% of the rest.
CAPA & Quality Systems

USP 788: particulate matter in injections, the limits, and what FDA cites

What USP 788 (particulate matter in injections) requires: Method 1 light obscuration and Method 2 microscopic particle count, the 10 µm and 25 µm limits per mL and per container, when Method 2 applies, and how USP 790 and USP 1790 cover visible particles. Adds Atlas data on 98 sterile drug inspections citing 21 CFR 211.113(b) from January 2025 to September 2026 and the 2026 warning letters that cited visual inspection programs.

Read more
Cleaning validation acceptance criteria cover: 10 ppm, 1/1000 dose and HBEL limits, with 237 of 774 FDA Part 211 drug inspections citing 21 CFR 211.67 and 40.5% of those ending OAI.
CAPA & Quality Systems

Cleaning validation acceptance criteria: 10 ppm, 1/1000 dose, HBEL and a worked MACO example

How cleaning validation acceptance criteria are set: the three legacy limits from FDA's 1993 inspection guide (10 ppm, 1/1000 of the dose, visually clean), the health-based exposure limit (PDE) approach in the EMA 2014 guideline and its 2018 questions and answers, a worked MACO to swab limit calculation with illustrative numbers, swab and rinse recovery, detergent and microbial limits, the three-run convention, and Atlas data on 21 CFR 211.67 citations and OAI outcomes at 774 drug inspections from January 2025 to September 2026.

Read more
Every USFDA warning letter to India, 2025 to 2026: 34 letters, 23 citing the quality unit, 16 to facilities already on Import Alert 66-40, and a 174-day median from inspection to letter.
Warning Letters & Enforcement

USFDA warning letters to Indian companies: all 34 CGMP letters from 2025 and 2026

A data roundup of the 34 FDA CGMP warning letters issued to facilities in India from January 1, 2025 to October 14, 2026: a full table by company, city and state, letter date, product type and main charges; counts by year and state; the violations FDA cites most often; the median gap from inspection to letter; India's OAI rate against the US; and links to each facility's Atlas inspection record where it is public.

Read more